The Shifting Landscape of HIV–Tuberculosis Co-Infection in the MENA Region with a Focus on Saudi Arabia: A Systematic Epidemiological Analysis over Three Decades Authors: Zikria Saleem, Masaad Saeed Almutairi, Huda Arooj, Faris S. Alnezary Published: 2026 ABSTRACT IntroductionThe interaction between human immunodeficiency virus (HIV) and tuberculosis (TB) presents a persistent public health challenge, particularly with the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The Middle East and North Africa (MENA) region shows complex TB patterns, and Saudi Arabia continues to face challenges in TB control within the regional context.MethodsUsing Global Burden of Disease (GBD) 2023 estimates, we analyzed age-standardized disability-adjusted life year (DALY) and incidence trends for HIV and drug-susceptible TB, MDR-TB, and XDR-TB in Saudi Arabia and the MENA region from 1990 to 2023. Temporal patterns were quantified using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC).ResultsAcross MENA and Saudi Arabia, the burden of drug-susceptible TB increased during the 1990s to early 2000s and subsequently declined in 2023 (MENA age-standardized DALY rate [ASDR]: 6.60 in 1990, peaking at 13.11 in 1999, declining to 7.39 in 2023; Saudi Arabia ASDR: 13.63 in 1990, peaking at 20.56 in 2003, declining to 4.94 in 2023). A similar temporal pattern was observed for MDR-TB (MENA ASDR (Age-Standardized DALY Rate): 0.03 in 1990, peaking at 1.04 in 2002, declining to 0.40 in 2023; Saudi Arabia ASDR: 0.03 in 1990, peaking at 1.93 in 2003, declining to 0.33 in 2023). In contrast, XDR-TB showed an overall decline in MENA (ASDR: 1.72 in 1991, declining to 0.02 in 2023), while in Saudi Arabia, ASDR declined from 2.42 in 1991 to 0.02 in 2023. MENA estimates are presented to provide regional context and enable comparison with national trends in Saudi Arabia.ConclusionsFrom 1990 to 2023, the TB burden among people with HIV in Saudi Arabia declined substantially, particularly for drug-susceptible TB, indicating progress in TB control and HIV management. Drug-resistant forms (MDR-TB and XDR-TB) showed complex trends with early increases followed by stabilization or gradual reductions in absolute burden.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40121-026-01358-9. Summary Points Why carry out this study?HIV and TB remain a major public health concern globally and in the Middle East and North Africa (MENA) region, with people with HIV facing a substantially higher risk of developing TB.Understanding the long-term trends and drug-resistant TB patterns among people with HIV is important for evaluating progress in TB control and HIV management in Saudi Arabia and the wider MENA region.This study aimed to assess temporal trends in the burden of TB among people with HIV, including drug-susceptible, multidrug-resistant, and extensively drug-resistant TB, in Saudi Arabia compared with the MENA region from 1990 to 2023.What was learned from the study?The burden of TB among people with HIV burden declined substantially in Saudi Arabia from 1990 to 2023, particularly for drug-susceptible TB, while multidrug-resistant and extensively drug-resistant TB remained comparatively low but showed distinct temporal patterns.The burden was concentrated in middle adulthood, with small but epidemiologically relevant signals observed in younger age groups; however, very low counts in some age categories limit definitive age-specific conclusions.These findings highlight the progress achieved in TB and HIV control in Saudi Arabia, while emphasizing the continued need for surveillance and strengthened strategies to monitor and manage drug-resistant tuberculosis in the region. Why carry out this study?HIV and TB remain a major public health concern globally and in the Middle East and North Africa (MENA) region, with people with HIV facing a substantially higher risk of developing TB.Understanding the long-term trends and drug-resistant TB patterns among people with HIV is important for evaluating progress in TB control and HIV management in Saudi Arabia and the wider MENA region.This study aimed to assess temporal trends in the burden of TB among people with HIV, including drug-susceptible, multidrug-resistant, and extensively drug-resistant TB, in Saudi Arabia compared with the MENA region from 1990 to 2023.What was learned from the study?The burden of TB among people with HIV burden declined substantially in Saudi Arabia from 1990 to 2023, particularly for drug-susceptible TB, while multidrug-resistant and extensively drug-resistant TB remained comparatively low but showed distinct temporal patterns.The burden was concentrated in middle adulthood, with small but epidemiologically relevant signals observed in younger age groups; however, very low counts in some age categories limit definitive age-specific conclusions.These findings highlight the progress achieved in TB and HIV control in Saudi Arabia, while emphasizing the continued need for surveillance and strengthened strategies to monitor and manage drug-resistant tuberculosis in the region. Introduction Tuberculosis (TB) remains a paramount global public health challenge, causing more deaths than any other single infectious agent [1]. While global efforts have led to a steady decline in incidence, the interaction between Mycobacterium tuberculosis and the human immunodeficiency virus (HIV) significantly complicates elimination efforts [2–4]. People with HIV are approximately 16 times more likely to develop TB disease than those without HIV [5]. According to the latest World Health Organization (WHO) Global TB Report, an estimated 10.8 million people fell ill with TB worldwide in 2023, with the proportion of people with HIV (PLWH) among these cases standing at 6.3% [6]. While TB-related mortality among individuals with HIV has declined to an estimated 161,000 deaths annually, it remains a leading cause of death among PLWH globally [6, 7]. The Middle East and North Africa (MENA) region presents a complex epidemiological landscape for TB, influenced by factors such as urbanization, migration, and political conflict [8]. Between 1990 and 2019, TB-related incidence, prevalence, death, and disability-adjusted life year (DALY) rates decreased by 53%, 42.19%, 76.20%, and 75.95% in the MENA region, respectively [8]. Within this region, Saudi Arabia has emerged as a leader in TB control through the implementation of robust national TB programs (NTP) [9]. The Kingdom successfully reduced its TB incidence from 44 per 100,000 in 1990 to approximately 14 per 100,000 by 2011, meeting early milestones for global elimination strategies [9]. Despite these successes, a significant reservoir of TB infection persists, with a pooled prevalence of 27% estimated across the MENA region, posing a continuous risk for reactivation [10]. The vulnerability of people with HIV in Saudi Arabia remains a concern, particularly as the Kingdom is classified among countries with an evolving “low-prevalence” HIV epidemic [11]. Although Saudi Arabia reports one of the lowest HIV prevalence rates worldwide, societal stigma and cultural sensitivities may influence reporting and prevention efforts, and disparities in HIV knowledge across demographic groups highlight the need for improved public health awareness and education [12]. In Saudi Arabia, same-sex relationships are legally prohibited and sociocultural stigma may influence HIV testing and reporting [13]. The estimated number of people with HIV in the Kingdom has grown notably, with a 26% increase in detected cases among Saudis reported in 2013 compared with 2012 [5]. Recent epidemiological data further indicate that 1633 new HIV cases were reported in the Eastern Province between 2014 and 2023, representing a > 2.5-fold increase during this period and underscoring the importance of strengthened surveillance and testing strategies [14]. Among people with HIV in Saudi Arabia, the risk of developing TB is estimated to be 30 times higher than in the general population [5]. Recent regional mapping indicates that while TB incidence is declining, the MENA region still faces challenges from “missing cases” and the specific burden of TB in high-risk groups such as people with HIV [15]. Furthermore, pulmonary TB is recognized as the most common acquired immunodeficiency syndrome (AIDS)-defining illness in the region, with its prevalence serving as a critical indicator of the healthcare system’s ability to manage co-infections [16]. Recent population-based surveys in major Saudi cities have reported significantly lower estimates for the prevalence of latent TB infection (LTBI) than the data suggested, with an overall prevalence of TB infection at 9.3% using tuberculin skin test (TST) and 9.1% using QuantiFERON TB Gold In-Tube test (QFT-GIT) (p = 0.872) [17]. A critical and evolving dimension of this co-infection in Saudi Arabia is the shifting landscape of drug resistance. The management of HIV and TB is increasingly hampered by the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains, which require complex and prolonged treatment regimens that challenge existing clinical protocols [3, 18–20]. Mortality among patients with TB in the Kingdom has been significantly associated with HIV co-infection, with long-term cohort data indicating that co-infected individuals face a threefold higher risk of death during treatment compared with those without HIV [11]. Data further indicate that approximately 29% of people with HIV in Saudi Arabia present with TB as their first AIDS-defining illness, underscoring the lethal synergy between these pathogens [16]. While the overall prevalence of TB infection in the Saudi general population has decreased significantly from 33.2% to approximately 9.1%, the intersection of this reservoir with an evolving HIV demographic remains a potent driver of active disease [17, 21]. Consequently, recent systematic analyses from the Global Burden of Disease (GBD) 2023 study emphasize that while the drug-susceptible TB burden is declining, the rising relative impact of drug-resistant forms measured through DALYs necessitates a recalibration of national health priorities [18]. While existing literature provides point-prevalence snapshots or clinical audits, there is a distinct lack of long-term, comparative evidence evaluating the burden of specific TB resistance categories among people with HIV in the MENA region [18]. This study addresses this gap by utilizing the GBD 2023 dataset to analyze three decades of epidemiological data from 1990 to 2023. Beyond the clinical implications, the emergence of MDR and XDR strains presents a profound pharmacoeconomic challenge, as the escalating direct and indirect costs associated with resistant cases threaten the sustainability of national health budgets and complicate the equitable allocation of specialized antimicrobial resources. By applying Joinpoint regression analysis, we quantify the temporal trends, specifically the annual percent change (APC) and average annual percent change (AAPC), for drug-susceptible TB, MDR-TB, and XDR-TB DALY rates among people with HIV. This systematic analysis compares the national experience of Saudi Arabia against broader MENA regional trends to provide essential evidence for refining public health policy and clinical interventions. Methods Regional Framework and Data Acquisition This study utilized estimates from the GBD 2023 study, coordinated by the institute for Health Metrics and Evaluation (IHME) [22], which provides comprehensive and internally consistent epidemiological estimates for 375 diseases and injuries across global populations. The GBD framework generates age–sex–location–year estimates using standardized analytical methods, enabling robust temporal and geographical assessments of disease burden [23]. For this study, age-standardized DALY rate estimates for TB were extracted from the Global Health Data Exchange (GHDx) results tool. Data were obtained for drug-susceptible TB, MDR-TB, and XDR-TB among people with HIV for the period 1990–2023. Ethical approval was not required for this study as it used publicly available, secondary data from Global Health Data Exchange (ghdx). All extracted data were stratified by location (Saudi Arabia and MENA) and resistance category (drug-susceptible TB, MDR-TB, and XDR-TB among people with HIV), calendar year, age-specific and age-standardized DALY and incidence rates. Case Definitions Incidence was defined as the number of newly occurring cases of disease within a specified population over a defined time period, while the incidence rate referred to the number of new cases per unit of population per unit of time. DALY is a composite measure capturing total health loss by summing years of life lost due to premature mortality and years lived with disability. DALYs therefore are a measure of the gap in healthy years of life lived by a population as compared with a normative standard. Inclusion and Exclusion Included were all GBD 2023 estimates of TB burden among people with HIV for Saudi Arabia and the MENA region from 1990 to 2023, including age-specific and age-standardized DALYs and incidence for drug-susceptible, multidrug-resistant, and extensively drug-resistant TB among people with HIV. Estimates encompassed both sexes and all age groups based on GBD-standardized definitions and uncertainty intervals, while TB estimates not attributable to HIV or not stratified by drug-resistance profile, extrapulmonary TB without HIV attribution, and noncomparable or incomplete time series data were excluded. An overview of the study design and analytical strategy is provided in Fig. 1.Fig. 1Schematic representation of the methodology. MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Schematic representation of the methodology. MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa This study was conducted using publicly available estimates from the GBD 2023, coordinated by the Institute for Health Metrics and Evaluation. The analyses presented in this manuscript were independently performed for the purposes of this study. The findings have not been previously presented at any conference or scientific meeting and have not been published elsewhere. This work therefore represents an original analysis of the available GBD data. Joinpoint Regression Analysis Temporal trends in age-standardized DALY and incidence rates for drug-susceptible TB, MDR-TB, and XDR-TB among people with HIV in Saudi Arabia and the MENA region from 1990 to 2023 were analyzed using Joinpoint regression models. Trends were quantified using the APC for each identified time segment and the AAPC for the entire study period, along with their corresponding 95% confidence intervals (95% CIs) (Supplementary Table S1 and S2). Joinpoint regression fits a series of segmented log-linear regression models to the temporal data, allowing for changes in trend at unknown time points (joinpoints). The model identifies calendar years in which statistically significant changes in the magnitude or direction of DALY rate trends occur and estimates separate linear trends within each segment. This approach enables characterization of disease-specific temporal patterns across distinct epidemiological phases. A log-linear model was specified, such that the natural logarithm of the age-standardized DALY rate was modeled as a function of calendar year. The optimal number and location of joinpoints were determined using the Monte Carlo permutation test, with an overall significance level of α = 0.05 (two-sided). The general form of the Joinpoint regression model is expressed as: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$E\left[ {Y|X} \right] = \exp \left( {\beta_{0} + \beta_{1} X + \delta_{1} \left( {X - \tau_{1} } \right)^{ + } + \cdots + \, \delta_{k} \left( {X - \tau_{k} } \right)^{ + } } \right)$$\end{document}EY|X=expβ0+β1X+δ1X-τ1++⋯+δkX-τk+ In the formula, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$e$$\end{document}e is the natural base, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$k$$\end{document}k represents the number of turning points, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\tau}_{k}$$\end{document}τk represents the unknown turning points, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\beta}_{0}$$\end{document}β0 is the invariant parameter, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\beta}_{1}$$\end{document}β1 is the regression coefficient, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\delta}_{k}$$\end{document}δk represents the regression coefficient of the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${k}^{th}$$\end{document}kth segmentation function.The APC for each segment was calculated as: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\mathrm{APC}} = \left( {e^{\beta } - 1} \right) \times 100$$\end{document}APC=eβ-1×100, where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document}β is the estimated regression coefficient for the corresponding time segment. The AAPC was computed as a weighted average of segment-specific APCs, with weights proportional to the length of each time interval. Calculation formula for AAPC is the following: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\mathrm{AAPC}} = \left[ {\exp \left( { \, \Sigma \left( {\omega_{i} \beta_{i} } \right)/\Sigma \omega_{i} } \right) - 1} \right] \times 100$$\end{document}AAPC=expΣωiβi/Σωi-1×100 A minimum of zero and a maximum of three joinpoints were allowed, depending on the length of the time series. All analyses assumed constant variance and uncorrelated errors. The methodology flowchart of the study is shown in Fig. 1 [24]. Statistical Software All statistical analyses and data visualizations were conducted using R software (version 4.4.1) and the Joinpoint Regression Program (version 5.4.0). A p value < 0.05 was considered statistically significant. Results Age-Specific Patterns of TB Burden among People with HIV in 2023 In 2023, drug-susceptible TB burden among people with HIV in Saudi Arabia increased from childhood to a peak in middle-aged adults, with DALY rates highest at 40–44 years (9.99 per 100,000) and 45–49 years (9.85), and a corresponding peak in incidence at 60–64 years (1.13). The MENA region showed the same age pattern but at higher levels, with DALYs peaking at 35–39 years (18.25) and incidence reaching its maximum at 40–44 years (2.10). In 2023, MDR-TB among people with HIV in Saudi Arabia showed its highest DALY rates among infants and middle-aged adults, with the greatest burden observed in children aged < 1 year (0.75 per 100,000), followed by adults aged 40–44 years (0.68 per 100,000), with incidence likewise peaking in middle adulthood (45–49 years: 0.021 per 100,000) and in the oldest age group (≥ 95 years: 0.022 per 100,000). In the MENA region, a similar age-concentrated pattern was observed, with DALY rates peaking in middle-aged adults, particularly those aged 35–39 years (0.99 per 100,000) and 40–44 years (0.97 per 100,000), accompanied by the highest incidence in adults aged 40–44 years (0.029 per 100,000). In 2023, DALY rates of XDR-TB among people with HIV in Saudi Arabia were 0.05 per 100,000 among adults aged 40–44 years and 0.06 per 100,000 among infants aged < 1 year. The highest incidence rates were observed in adults aged 45–49 years (0.0013 per 100,000) and those aged ≥ 95 years (0.0016 per 100,000). In the MENA region, DALY rates were highest in middle adulthood (35–39 and 40–44 years: 0.07 per 100,000), with incidence likewise peaking at 40–44 years (0.0018 per 100,000) and remaining very low at younger and older ages (Fig. 2).Fig. 2Age-specific DALYs and incidence rates of HIV-associated drug-susceptible TB, MDR-TB, and XDR-TB in Saudi Arabia and the MENA region for 2023. MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Age-specific DALYs and incidence rates of HIV-associated drug-susceptible TB, MDR-TB, and XDR-TB in Saudi Arabia and the MENA region for 2023. MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Temporal Trends in Tuberculosis Burden among People with HIV (1990–2023) In Saudi Arabia, drug-susceptible TB among people with HIV declined markedly, with age-standardized DALY rate (Age-Standardized DALY Rate) decreasing from 13.6 per 100,000 in 1990 to 4.9 per 100,000 in 2023, accompanied by a parallel reduction in age-standardized incidence rate (Age-Standardized Incidence Rate) from 1.44 to 0.56 per 100,000. At the regional level, drug-susceptible TB in MENA also showed a gradual downward trend but remained comparatively higher throughout the period (ASDR: 6.6–7.4; ASIR: 0.72–0.90). In contrast, MDR-TB among people with HIV rose sharply from near-negligible levels in the early 1990s (Saudi Arabia ASDR: 0.03; ASIR < 0.001) to peak values in the early 2000s (ASDR approximately 1.9; ASIR approximately 0.05), followed by a slow decline in 2023 (ASDR 0.33; ASIR 0.01). XDR-TB emerged later with extremely low initial rates, increased modestly by the mid-2000s, and subsequently stabilized at low but persistent levels by 2023 (ASDR: 0.02; ASIR: 0.0006) (Fig. 3).Fig. 3Trends in Age-Standardized DALY Rate and Age-Standardized Incidence Rate of HIV-associated drug-susceptible TB, MDR-TB, and XDR-TB in Saudi Arabia and the MENA region for 1990–2023. MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Trends in Age-Standardized DALY Rate and Age-Standardized Incidence Rate of HIV-associated drug-susceptible TB, MDR-TB, and XDR-TB in Saudi Arabia and the MENA region for 1990–2023. MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Joinpoint trend analysis from 1990 to 2023 reveals that drug-susceptible TB followed a classic epidemic pattern, with early increases during the 1990s and early 2000s transitioning into sustained and statistically significant declines in both DALY and incidence rates in later years, reflected by a negative long-term AAPC for DALYs (−3.20%) and incidence (−2.97%) in Saudi Arabia. In contrast, MDR-TB among people with HIV demonstrated a fundamentally different course, marked by rapid early expansion, followed by gradual declines, in both DALYs (AAPC +7.44%) and incidence (+7.58%). XDR-TB maintained strongly positive long-term trends in both burden and incidence (DALY AAPC +34.26%; incidence AAPC +21.38%) (Table 1). Table 1APC and AAPC Estimates for ASDR and ASIR of HIV–TB Co‑Infection in Saudi Arabia and the MENA RegionTB categoryMeasureDALYsDALYsIncidenceIncidenceSaudi ArabiaMENA regionSaudi ArabiaMENA regionHIV + drug-susceptible TBKey APC periods (%)1990–2003: +2.302003–2010: −3.402010–2020: −9.612020–2023: −3.77 (NS)1990–1993: +15.871993–1997: +6.401997–2013: −1.012013–2023: −4.721990–2001: −0.15 (NS)2001–2005: +4.782005–2011: −2.722011–2023: −8.011990–1994: +9.191994–2002: +2.552002–2014: −0.242014–2023: −3.61AAPC (1990–2023)−3.20%(−3.38 to −3.04)0.13%(−0.01 to 0.31) (NS)−2.97% (−3.05 to −2.90)+0.59% (0.51 to 0.68)HIV + MDR-TBKey APC periods (%)1990–1996: +64.201996–2002: +21.662002–2020: −8.82 (NS)2020–2023: −4.02 (NS)1990–1996: +60.281996–2001: +13.992001–2008: −7.192008–2023: −3.321990–1994: +66.951994–1998: +39.461998–2002: +16.322002–2023: −7.231990–1995: +52.891995–2000: +21.862000–2009: −5.622009–2023: −2.67AAPC (1990–2023)+7.44% (6.98 to 7.79)+7.73% (7.49 to 8.03)+7.58% (7.34 to 7.93)+6.93% (6.66 to 7.28)HIV + XDR-TBKey APC periods (%)1991–1994: +847.101994–2001: +62.112001–2023: −3.121991–1994: +988.101994–2000: +54.072000–2023: +1.16 (NS)1991–1994: +185.631994–1997: +95.821997–2002: +39.632002–2023: −2.981991–1994: +169.911994–1997: +86.581997–2001: +29.562001–2023: +1.23AAPC (1991–2023)+34.26% (32.39 to 36.50)+36.77% (34.46 to 39.59)+21.38% (20.79 to 22.00)+21.21% (20.79 to 21.77)DALY rates were age-standardized using the Global Burden of Disease (GBD) standard population. APCs and AAPCs were estimated using log-linear Joinpoint regression with Monte Carlo permutation tests (overall significance level 0.05). Extremely large APCs observed in early years reflect very low baseline rates and should be interpreted as early epidemic expansion rather than literal proportional increases. Nonstatistically significant estimates are marked with as “(NS)”. Positive APC or AAPC values indicate an upward trend, whereas negative values indicate a downward trend over timeDALY disability-adjusted life year, APC annual percent change, AAPC average annual percent change, CI confidence interval, MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Table 1APC and AAPC Estimates for ASDR and ASIR of HIV–TB Co‑Infection in Saudi Arabia and the MENA RegionTB categoryMeasureDALYsDALYsIncidenceIncidenceSaudi ArabiaMENA regionSaudi ArabiaMENA regionHIV + drug-susceptible TBKey APC periods (%)1990–2003: +2.302003–2010: −3.402010–2020: −9.612020–2023: −3.77 (NS)1990–1993: +15.871993–1997: +6.401997–2013: −1.012013–2023: −4.721990–2001: −0.15 (NS)2001–2005: +4.782005–2011: −2.722011–2023: −8.011990–1994: +9.191994–2002: +2.552002–2014: −0.242014–2023: −3.61AAPC (1990–2023)−3.20%(−3.38 to −3.04)0.13%(−0.01 to 0.31) (NS)−2.97% (−3.05 to −2.90)+0.59% (0.51 to 0.68)HIV + MDR-TBKey APC periods (%)1990–1996: +64.201996–2002: +21.662002–2020: −8.82 (NS)2020–2023: −4.02 (NS)1990–1996: +60.281996–2001: +13.992001–2008: −7.192008–2023: −3.321990–1994: +66.951994–1998: +39.461998–2002: +16.322002–2023: −7.231990–1995: +52.891995–2000: +21.862000–2009: −5.622009–2023: −2.67AAPC (1990–2023)+7.44% (6.98 to 7.79)+7.73% (7.49 to 8.03)+7.58% (7.34 to 7.93)+6.93% (6.66 to 7.28)HIV + XDR-TBKey APC periods (%)1991–1994: +847.101994–2001: +62.112001–2023: −3.121991–1994: +988.101994–2000: +54.072000–2023: +1.16 (NS)1991–1994: +185.631994–1997: +95.821997–2002: +39.632002–2023: −2.981991–1994: +169.911994–1997: +86.581997–2001: +29.562001–2023: +1.23AAPC (1991–2023)+34.26% (32.39 to 36.50)+36.77% (34.46 to 39.59)+21.38% (20.79 to 22.00)+21.21% (20.79 to 21.77)DALY rates were age-standardized using the Global Burden of Disease (GBD) standard population. APCs and AAPCs were estimated using log-linear Joinpoint regression with Monte Carlo permutation tests (overall significance level 0.05). Extremely large APCs observed in early years reflect very low baseline rates and should be interpreted as early epidemic expansion rather than literal proportional increases. Nonstatistically significant estimates are marked with as “(NS)”. Positive APC or AAPC values indicate an upward trend, whereas negative values indicate a downward trend over timeDALY disability-adjusted life year, APC annual percent change, AAPC average annual percent change, CI confidence interval, MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa APC and AAPC Estimates for ASDR and ASIR of HIV–TB Co‑Infection in Saudi Arabia and the MENA Region 1990–2003: +2.30 2003–2010: −3.40 2010–2020: −9.61 2020–2023: −3.77 (NS) 1990–1993: +15.87 1993–1997: +6.40 1997–2013: −1.01 2013–2023: −4.72 1990–2001: −0.15 (NS) 2001–2005: +4.78 2005–2011: −2.72 2011–2023: −8.01 1990–1994: +9.19 1994–2002: +2.55 2002–2014: −0.24 2014–2023: −3.61 −3.20% (−3.38 to −3.04) 0.13% (−0.01 to 0.31) (NS) 1990–1996: +64.20 1996–2002: +21.66 2002–2020: −8.82 (NS) 2020–2023: −4.02 (NS) 1990–1996: +60.28 1996–2001: +13.99 2001–2008: −7.19 2008–2023: −3.32 1990–1994: +66.95 1994–1998: +39.46 1998–2002: +16.32 2002–2023: −7.23 1990–1995: +52.89 1995–2000: +21.86 2000–2009: −5.62 2009–2023: −2.67 1991–1994: +847.10 1994–2001: +62.11 2001–2023: −3.12 1991–1994: +988.10 1994–2000: +54.07 2000–2023: +1.16 (NS) 1991–1994: +185.63 1994–1997: +95.82 1997–2002: +39.63 2002–2023: −2.98 1991–1994: +169.91 1994–1997: +86.58 1997–2001: +29.56 2001–2023: +1.23 DALY rates were age-standardized using the Global Burden of Disease (GBD) standard population. APCs and AAPCs were estimated using log-linear Joinpoint regression with Monte Carlo permutation tests (overall significance level 0.05). Extremely large APCs observed in early years reflect very low baseline rates and should be interpreted as early epidemic expansion rather than literal proportional increases. Nonstatistically significant estimates are marked with as “(NS)”. Positive APC or AAPC values indicate an upward trend, whereas negative values indicate a downward trend over time DALY disability-adjusted life year, APC annual percent change, AAPC average annual percent change, CI confidence interval, MDR-TB multidrug-resistant tuberculosis, XDR-TB extensively drug-resistant tuberculosis, MENA Middle East and North Africa Discussion The present analysis demonstrates age-dependent concentration of tuberculosis burden among people with HIV, consistent with epidemiological patterns in Saudi Arabia and the MENA region. In 2023, drug-susceptible HIV–TB burden peaked in middle-aged adults, while regional estimates showed higher levels within similar age groups. This pattern corresponds with Saudi HIV surveillance data indicating that infections are predominantly clustered among adults aged 30–44 years. This observation is further reinforced by national prevalence data identifying age as a key determinant of TB infection, with higher prevalence observed in older adults [14, 25]. Evidence from other high-burden settings further supports the biological plausibility of this age gradient, where HIV–TB co-infection and advancing age have been shown to adversely influence treatment success, particularly among adults not receiving antiretroviral therapy, underscoring the broader clinical relevance of age in HIV–TB interactions [26–28]. Complementing these adult-centered patterns, pediatric evidence from Saudi Arabia underscores the predominance of perinatal HIV transmission and highlights the pivotal role of timely diagnosis and preventive interventions in shaping long-term clinical trajectories among children [29]. The infant burden of MDR-TB and XDR-TB, though small, is epidemiologically significant, as pediatric drug-resistant TB often indicates recent transmission [30, 31]. Despite low national TB incidence, even minimal resistant TB burdens carry substantial public health importance [32]. The temporal trajectories identified over three decades provide further insight into the evolving HIV–TB landscape. The marked decline of drug-susceptible TB mortality and incidence among people with HIV in Saudi Arabia reflects substantial progress in TB control and HIV management, consistent with documented national reductions in TB incidence following End TB Strategy implementation [33, 34]. Earlier reports also noted limited HIV screening among patients with TB, even though the proportion of detected co-infection was low, pointing to potential gaps in case identification [35]. Improvements in diagnostic infrastructure, treatment coverage, and antiretroviral therapy access have likely contributed decline of TB disease [36, 37]. However, the contrasting expansion of MDR-TB and XDR-TB among people with HIV signals a more complex epidemiological shift. Similar concerns have been raised across Middle Eastern countries, where conflict, migration, and heterogeneous healthcare access complicate TB elimination efforts [31]. Drug resistance trends frequently decouple from overall TB incidence because they are driven by distinct mechanisms, including prior treatment exposure, programmatic weaknesses, and transmission of resistant strains. Saudi surveillance data have indeed reported declining resistance to first-line drugs in recent years [33]. This study offers several policy-relevant strengths, notably the use of the GBD 2023 framework, which ensures standardized, internally consistent, and comparable estimates across populations and time, enabling credible long-term evaluation. The three-decade analytical horizon captures structural epidemiological transitions essential for strategic planning, while resistance-stratified assessment of drug-susceptible TB, MDR-TB, and XDR-TB within an HIV context provides actionable insights for resource allocation and program prioritization. Joinpoint regression further strengthens inference by identifying statistically meaningful shifts in trends rather than assuming uniform temporal change. However, this study also has some limitations. Policymakers should interpret findings with recognition that GBD estimates are model-derived and sensitive to input data quality, and that potential misclassification or under-ascertainment may influence magnitude estimates. In addition, sociocultural stigma and legal sensitivities surrounding HIV, particularly in relation to same-sex relationships, may contribute to underreporting, reduced healthcare-seeking behavior, and fear of testing, potentially leading to underestimation of the true incidence and prevalence of HIV and people with HIV and tuberculosis. Additionally, several age groups showed very small absolute numbers and rates, which limits the ability to draw definitive conclusions regarding age-specific trends. Conclusions From 1990 to 2023, the burden of tuberculosis among people with HIV in Saudi Arabia showed a substantial decline, particularly for drug-susceptible TB, reflecting progress in TB control and HIV management. However, drug-resistant forms, including MDR-TB and XDR-TB, displayed complex temporal patterns characterized by early increases followed by stabilization or gradual reductions in absolute burden over time. Age-specific patterns indicated that the burden was concentrated primarily among middle-aged adults; however, the absolute numbers and rates in several age groups were very small, which limits the ability to draw a definitive conclusion regarding specific age-group trends. These findings highlight the importance of sustained surveillance, strengthened antimicrobial resistance control strategies, and targeted interventions for high-risk age groups to further reduce TB among people with HIV. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 260 KB) Supplementary file1 (PDF 260 KB)